Printer Friendly

Gene expression helps classify cancers.

Only about 60 percent of people with diffuse large B-cell lymphoma, a common cancer of white blood cells, respond well to therapy. This cancer, as currently defined, is in fact two distinct diseases, according to new tests that use so-called gene chips to look at the activity of thousands of genes simultaneously. Patients with one pattern of gene expression, called germinal-center B-like pattern, seem to respond better to treatment than the other patients do, says R. Eric Davis of the National Cancer Institute in Bethesda, Md.

Among 19 people with germinal-center B-like disease, 14 were still alive 5 years after diagnosis, he and his colleagues report in the Feb. 3 NATURE. In contrast, only 3 of 19 patients with so-called activated B-like disease survived for 5 years.

The team hopes that gene chips will illuminate the cellular pathways that give rise to the slightly different cancers and those results will lead to more successful therapies.
COPYRIGHT 2000 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:diffuse large B-cell lymphoma
Author:D.C.
Publication:Science News
Article Type:Brief Article
Date:Apr 8, 2000
Words:155
Previous Article:Antacids for asthma sufferers?
Next Article:Telltale Dino Heart Hints at Warm Blood.
Topics:


Related Articles
Genetic roadblocks: the body may not always resist cancer, but it does have built-in barricades to slow the spread.
Four steps to lymphoma.
Life-or-death gene sheds light on lymphoma.
Gene for rare disease gives cancer clues.
Drug aids destruction of lymphoma cells.
Genes make potential target in lymph cancer. (Science News of the week).
Targeted therapies: will gene screens usher in personalized medicine?
Primary non-Hodgkin lymphoma of the larynx.
Cancer link: microRNA grabs the spotlight.
MALT lymphomas--a closer look in the Genomics era.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters